公开(公告)号：DE60137421D1

公开(公告)日：2009-03-05

申请号：DE60137421

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: C12N15/13 ,  G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：BG107483A

公开(公告)日：2003-09-30

申请号：BG10748303

申请日：2003-01-21

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD W ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/577 ,  A61K51/10 ,  C12N15/63

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1alpha and IL-1beta and neutralize IL-1alpha and IL-1beta activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1alpha and IL-1beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1alpha and/or IL-1beta activity is detrimental. 88 claims

公开(公告)号：CZ292465B6

公开(公告)日：2003-09-17

申请号：CZ247698

申请日：1997-02-10

Applicant: ABBOTT LAB BERMUDA LTD

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINNESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13 ,  C12N15/64

Abstract: Human antibodies, preferably recombinant human antibodies that specifically bind to human tumor necrosis factor alpha (hTNF alpha) are described. These antibodies have high affinity for hTNF alpha (e.g., Kid = =10e-3se-1 or less), a slow off rate for hTNF alpha dissociation (e.g., Koff = 10 sec or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：DK0929578T3

公开(公告)日：2003-08-25

申请号：DK97906572

申请日：1997-02-10

Applicant: ABBOTT LAB BERMUDA LTD

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13 ,  C12N15/64

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：SK1152003A3

公开(公告)日：2003-07-01

申请号：SK1152003

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/577 ,  A61K51/10 ,  C12N15/63

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：BR0112026A

公开(公告)日：2003-05-20

申请号：BR0112026

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/577 ,  A61K51/10 ,  C12N15/63

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：PE20020132A1

公开(公告)日：2002-03-04

申请号：PE2001000641

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： AVGERINOS GEORGE ,  COLLINSON ALBERT ,  GHAYUR TARIQ ,  KAYMAKCALAN ZEHRA ,  DIXON RICHARD

IPC: G01N33/50 ,  A01K67/027 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K14/545 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

Abstract: SE REFIERE A UN ANTICUERPO DE ESPECIFIDAD DOBLE O UNA PORCION DEL MISMO DE UNION A ANTIGENO CARACTERIZADO PORQUE SE UNE A LA INTERLEUQUINA 1a Y INTERLUQUINA-1b CON UNA CONSTANTE DE VELOCIDAD Koff DE 0,1s-1 O MENOS O QUE INHIBE LA ACTIVIDAD DE INTERLEUQUINA-1a CON UNA IC50 DE 1*10-5 O MENOS. TAMBIEN SE REFIERE A UN METODO PARA OBTENER UN ANTICUERPO DE ESPECIFICIDAD DOBLE QUE SE UNE ESPECIFICAMENTE A INTERLEUQUINA-1a Y INTERLEUQUINA-1b O DOS MOLECULAS DIFERENTES PERO RELACIONADAS DESDE EL PUNTO DE VISTA ESTRUCTURAL QUE COMPRENDE PROVEER UN ANTIGENO CON UNA CARACTERISTICA ESTRUCTURAL COMUN DE IL-1a E IL-1b; EXPONER UN REPERTORIO DE ANTICUERPOS AL ANTIGENO IN VIVO INMUNIZANDO AL ANIMAL O PONER EN CONTACTO LA MUESTRA O TEJIDO BIOLOGICO SOSPECHADO DE CONTENER IL-1a E IL-1b CON EL ANTICUERPO DE ESPECIFICIDAD DOBLE

公开(公告)号：UY26807A1

公开(公告)日：2002-01-31

申请号：UY26807

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： AVGERINOS GEORGE ,  GHAYUR TARIQ ,  COLLINSON ALBERT ,  KAYMAKCALAN ZEHRA ,  DIXON RICHARD

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  C07K16/34

Abstract: Se proveen : anticuerpos teniendo especificidad doble por dos antígenos diferentes pero relacionados desde el punto de vista estructural, pueden ser, por ejemplo, anticuerpos humanos completos, anticuerpos recombinantes o anticuerpos monoclonales. Los preferidos tienen especificidad doble por IL 1 & e IL 1B y neutralizan la actividad de IL & e IL 1B in vitro e in vivo. Un anticuerpo puede ser un anticuerpo o una porción de unión a antígeno del mismo. Métodos para preperar y usar los anticuerpos referidos. Ellos son útiles para detectar dos antígenos diferentes pero relacionados desde el punto de vista estructural ( por ejemplo IL 1& E IL 1B) y para inhibir la actividad de los antígenos.

公开(公告)号：CA2411374A1

公开(公告)日：2002-01-10

申请号：CA2411374

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： KAYMAKCALAN ZEHRA ,  DIXON RICHARD ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  COLLINSON ALBERT

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  A01K67/027 ,  A61K51/10 ,  C07K14/545 ,  G01N33/577 ,  C12N15/63

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：AT420958T

公开(公告)日：2009-01-15

申请号：AT01950668

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: C12N15/13 ,  G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.